Lenogastrim ( DrugBank: - )

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
28全身性アミロイドーシス1

28. 全身性アミロイドーシス

臨床試験数 : 261 /  薬物数 : 276 - (DrugBank : 81) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 178
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2006-006395-37-GB
(EUCTR)		06/09/200731/07/2007A randomised, multi-centre feasibility trial in AL Amyloidosis, comparing CTD with SCT in patients with low risk of Treatment Related Mortality and CTD with Mel-Dex in patients in whom SCT would not be considered appropriate as first line therapy - UK Amyloidosis Treatment Trial (UKATT)A randomised, multi-centre feasibility trial in AL Amyloidosis, comparing CTD with SCT in patients with low risk of Treatment Related Mortality and CTD with Mel-Dex in patients in whom SCT would not be considered appropriate as first line therapy - UK Amyloidosis Treatment Trial (UKATT) The medical condition to be investigated is systemic AL Amyloidosis, a disorder of protein folding in which normally soluble proteins are deposited as abnormal, insoluble fibrils that progressively disrupt tissue structure and impair function.
MedDRA version: 9.1;Level: LLT;Classification code 10002022;Term: Amyloidosis 		Product Name: Cyclophosphamide
INN or Proposed INN: CYCLOPHOSPHAMIDE
Product Name: Cyclophosphamide
INN or Proposed INN: CYCLOPHOSPHAMIDE
Product Name: Dexamethasone
INN or Proposed INN: DEXAMETHASONE
Product Name: Dexamethasone
INN or Proposed INN: DEXAMETHASONE
Trade Name: Lenogastrim
Other descriptive name: GRANULOCYTE COLONY STIMULATING FACTOR
Product Name: Melphalan
INN or Proposed INN: MELPHALAN		Joint UCLH and UCL Biomedical Research UnitNULLNot Recruiting Female: yes
Male: yes		48 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noUnited Kingdom